Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at?

PubWeight™: 0.81‹?›

🔗 View Article (PMID 23777736)

Published in Glob J Health Sci on May 15, 2013

Authors

Sonia Menon1

Author Affiliations

1: University of Ghent, Ghent, Belgium. soniamenon1@yahoo.com

Articles cited by this

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med (1992) 13.29

Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med (2000) 10.50

Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep (2005) 8.91

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 5.01

Molecular epidemiology of tuberculosis. N Engl J Med (2003) 4.70

Multidrug-resistant tuberculosis. Ann Intern Med (1992) 4.06

Natural ventilation for the prevention of airborne contagion. PLoS Med (2007) 3.73

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67

Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet (2007) 3.65

Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med (2008) 3.04

Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis (2004) 2.87

Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis (2007) 2.79

Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One (2009) 2.51

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One (2009) 2.47

Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest (1997) 2.42

Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis (2009) 2.22

Evaluation of N95 respirator use as a tuberculosis control measure in a resource-limited setting. Int J Tuberc Lung Dis (2005) 1.93

Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: has WHO offered a milestone for HIV prevention? J Public Health Policy (2010) 1.79

High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis (2001) 1.78

Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics (2002) 1.74

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68

Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med (2007) 1.46

Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. BMC Res Notes (2012) 1.22

HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis (2012) 1.19

The costs of healthcare worker respiratory protection and fit-testing programs. Infect Control Hosp Epidemiol (1998) 1.18

Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One (2009) 1.16

Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr Infect Dis J (1999) 1.14

Tuberculosis infection control in primary health clinics in eThekwini, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis (2012) 1.12

Professional and home-made face masks reduce exposure to respiratory infections among the general population. PLoS One (2008) 1.12

Impact of environmental factors on efficacy of upper-room air ultraviolet germicidal irradiation for inactivating airborne mycobacteria. Environ Sci Technol (2005) 1.11

The history of ultraviolet germicidal irradiation for air disinfection. Public Health Rep (2010) 1.11

Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis (1999) 1.08

The status of tuberculosis infection control measures in health care facilities rendering joint TB/HIV services in "German Leprosy and Tuberculosis Relief Association" supported states in Nigeria. Niger J Clin Pract (2011) 0.94

Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis (2006) 0.92

Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment. Int J Tuberc Lung Dis (2009) 0.84

Assessment of organizational measures to prevent nosocomial tuberculosis in health facilities of 4 sub-Saharan countries in 2010. Infect Control Hosp Epidemiol (2012) 0.84

Treatment and prevention of tuberculosis in HIV-infected persons. Infect Dis Clin North Am (1994) 0.80